259 related articles for article (PubMed ID: 9661818)
21. No evidence for multiple-drug prophylaxis for tuberculosis compared with isoniazid alone in Southeast Asian refugees and migrants: completion and compliance are major determinants of effectiveness.
MacIntyre CR; Ansari MZ; Carnie J; Hart WG
Prev Med; 2000 May; 30(5):425-32. PubMed ID: 10845752
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis.
Gourevitch MN; Hartel D; Selwyn PA; Schoenbaum EE; Klein RS
AIDS; 1999 Oct; 13(15):2069-74. PubMed ID: 10546859
[TBL] [Abstract][Full Text] [Related]
23. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.
Salpeter SR; Sanders GD; Salpeter EE; Owens DK
Ann Intern Med; 1997 Dec; 127(12):1051-61. PubMed ID: 9412307
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of compliance with antituberculous chemoprophylaxis among recluse population of the Jaen penitentiary center].
Romero Saldaña M; Vaquero Abellán M; Gallego Rubio R; Aguilera López MD; de Celis Cornejo JM; Barquín García E; Zurita Serrano R
Rev Esp Salud Publica; 1997; 71(4):391-9. PubMed ID: 9490193
[TBL] [Abstract][Full Text] [Related]
25. The cost-effectiveness of DOTS in urban Brazil.
Mohan CI; Bishai D; Cavalcante S; Chaisson RE
Int J Tuberc Lung Dis; 2007 Jan; 11(1):27-32. PubMed ID: 17217126
[TBL] [Abstract][Full Text] [Related]
26. Effect of directly observed preventive therapy for latent tuberculosis infection in San Francisco.
White MC; Gournis E; Kawamura M; Menendez E; Tulsky JP
Int J Tuberc Lung Dis; 2003 Jan; 7(1):30-5. PubMed ID: 12701832
[TBL] [Abstract][Full Text] [Related]
27. Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients--a least-cost analysis.
Masobe P; Lee T; Price M
S Afr Med J; 1995 Feb; 85(2):75-81. PubMed ID: 7597538
[TBL] [Abstract][Full Text] [Related]
28. Prophylaxis of mycobacterial infections in immunocompromised patients.
Krance MB; Fisher MA
Am Fam Physician; 1996 Nov; 54(6):1981-8, 1991-2. PubMed ID: 8900358
[TBL] [Abstract][Full Text] [Related]
29. Update on the treatment of tuberculosis.
Inge LD; Wilson JW
Am Fam Physician; 2008 Aug; 78(4):457-65. PubMed ID: 18756652
[TBL] [Abstract][Full Text] [Related]
30. A risk/cost analysis of alternative screening intervals for occupational tuberculosis infection.
Nicas M
Am Ind Hyg Assoc J; 1998 Feb; 59(2):104-12. PubMed ID: 9487664
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.
Azadi M; Bishai DM; Dowdy DW; Moulton LH; Cavalcante S; Saraceni V; Pacheco AG; Cohn S; Chaisson RE; Durovni B; Golub JE
Int J Tuberc Lung Dis; 2014 Dec; 18(12):1443-8. PubMed ID: 25517809
[TBL] [Abstract][Full Text] [Related]
32. Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis.
Fallab-Stubi CL; Zellweger JP; Sauty A; Uldry C; Iorillo D; Burnier M
Int J Tuberc Lung Dis; 1998 Jul; 2(7):525-30. PubMed ID: 9661817
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of the russian treatment scheme for tuberculosis versus short-course chemotherapy: results from Tomsk, Siberia.
Jacobs B; Clowes C; Wares F; Polivakho V; Lyagoshina T; Peremitin G; Banatvala N
Int J Tuberc Lung Dis; 2002 May; 6(5):396-405. PubMed ID: 12019915
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of isoniazid chemoprevention in close contacts.
Diel R; Nienhaus A; Schaberg T
Eur Respir J; 2005 Sep; 26(3):465-73. PubMed ID: 16135730
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of different treatment strategies for tuberculosis in Egypt and Syria.
Vassall A; Bagdadi S; Bashour H; Zaher H; Maaren PV
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1083-90. PubMed ID: 12546116
[TBL] [Abstract][Full Text] [Related]
36. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy.
Vikrant S; Agarwal SK; Gupta S; Bhowmik D; Tiwari SC; Dash SC; Guleria S; Mehta SN
Transpl Infect Dis; 2005; 7(3-4):99-108. PubMed ID: 16390397
[TBL] [Abstract][Full Text] [Related]
37. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program.
Gourevitch MN; Wasserman W; Panero MS; Selwyn PA
J Addict Dis; 1996; 15(1):93-104. PubMed ID: 8729149
[TBL] [Abstract][Full Text] [Related]
38. Directly observed isoniazid preventive therapy for released jail inmates.
Nolan CM; Roll L; Goldberg SV; Elarth AM
Am J Respir Crit Care Med; 1997 Feb; 155(2):583-6. PubMed ID: 9032198
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.
Pinkerton SD; Martin JN; Roland ME; Katz MH; Coates TJ; Kahn JO
Arch Intern Med; 2004 Jan; 164(1):46-54. PubMed ID: 14718321
[TBL] [Abstract][Full Text] [Related]
40. Management of latent tuberculosis infection in immigrants.
Menzies D; Schwartzman K
N Engl J Med; 2003 Mar; 348(13):1289-92; author reply 1289-92. PubMed ID: 12661572
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
